Evidence map›Paper›PMID 29378537›Full record

ArticleBMC public health2018

Comprehensive economic evaluation of thermotherapy for the treatment of cutaneous leishmaniasis in Colombia.

Jaiberth Antonio Cardona-Arias, Liliana López-Carvajal, Mery Patricia Tamayo-Plata, Iván Darío Vélez

Open access · goldAbstract read
In one paragraph

Article in BMC public health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Heat therapy for cutaneous leishmaniasis: A literature Review.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2021
    Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jaiberth Antonio Cardona-AriasUniversidad de Antioquia, Universidad Cooperativa de Colombia, Medellin, Colombia. jaiberthcardona@gmail.co.
Liliana López-CarvajalPECET Program for the Study and Control of Tropical Diseases, University of Antioquia, Medellin, Colombia.
Mery Patricia Tamayo-PlataSchool of Economics and Finance, EAFIT University, Medellin, Colombia.
Iván Darío VélezPECET Program for the Study and Control of Tropical Diseases, University of Antioquia, Medellin, Colombia.
Universidad de Antioquia · COUniversidad EAFIT · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCutaneous leishmaniasis causes a high disease burden in Colombia, and available treatments present systemic toxicity, low patient compliance, contraindications, and high costs. The purpose of this study was to estimate the cost-effectiveness of thermotherapy versus Glucantime in patients with cutaneous leishmaniasis in Colombia.

methodsCost-effectiveness study from an institutional perspective in 8133 incident cases. Data on therapeutic efficacy and safety were included, calculating standard costs; the outcomes were disability adjusted life years (DALYs) and the number of patients cured. The information sources were the Colombian Public Health Surveillance System, disease burden studies, and one meta-analysis of controlled clinical trials. Incremental cost-effectiveness was determined, and uncertainty was evaluated with tornado diagrams and Monte Carlo simulations.

resultsThermotherapy would generate costs of US$ 501,621; the handling of adverse effects, US$ 29,224; and therapeutic failures, US$ 300,053. For Glucantime, these costs would be US$ 2,731,276, US$ 58,254, and US$ 406,298, respectively. With thermotherapy, the cost would be US$ 2062 per DALY averted and US$ 69 per patient cured; with Glucantime, the cost would be US$ 4241 per DALY averted and US$ 85 per patient cured. In Monte Carlo simulations, thermotherapy was the dominant strategy for DALYs averted in 67.9% of cases and highly cost-effective for patients cured in 72%.

conclusionIn Colombia, thermotherapy can be included as a cost-effective strategy for the management of cutaneous leishmaniasis. Its incorporation into clinical practice guidelines could represent savings of approximately US$ 10,488 per DALY averted and costs of US$ 116 per additional patient cured, compared to the use of Glucantime. These findings show the relevance of the incorporation of this treatment in our country and others with similar parasitological, clinical, and epidemiological patterns.

Indexed as

ColombiaCost-Benefit AnalysisHumansHyperthermia, InducedLeishmaniasis, CutaneousMeglumineMeglumine AntimoniateOrganometallic CompoundsPersons with DisabilitiesQuality-Adjusted Life YearsTreatment OutcomeMeglumineMeglumine AntimoniateOrganometallic CompoundsColombiaCost-effectiveness evaluationCutaneous leishmaniasisSodium antimony gluconateThermotherapy

Identifiers

PMID29378537
PMCPMC5789596
OpenAlexW2796588292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.